MORRISVILLE, N.C. – June 3, 2021 – Metabolon, Inc., the global leader in metabolomics solutions advancing drug development and precision medicine, has named two new executives to support its mission to become a diversified leader in healthcare: Florina Krawchick, SPHR, CPC, Vice President, Global Head of Human Resources and J. Kevin Day, Ph.D., HCLD (ABB)., Vice President, Operations.
“I am very pleased to welcome Florina and Kevin to our team. Both bring critical expertise in areas of significant strategic importance to us: Florina brings deep experience growing companies and their people through change, while Kevin brings expertise in clinical laboratory operations, Lean Six Sigma methodologies and clinical testing,” says Rohan Hastie, President & CEO, Metabolon. “I am confident their leadership will help accelerate our ambitious growth strategies in biomarker-based drug development and precision medicine.”
Krawchick’s experience includes leading companies through a broad range of business environments, including mergers and acquisitions, IPO and growth. Her role will focus on aligning the needs of our team members with business objectives and further strengthening the company’s values-based culture of purpose, performance and passion. “Metabolon is at the intersection of life sciences and technology, and I am honored to join the team at this time of growth,” says Krawchick. “As we prioritize objectives for 2021 and beyond, we are fully committed to enabling a strong team and inclusive culture at Metabolon. I look forward to collaborating with our team to support our mission to change the lives of patients.”
Metabolon leverages its leading metabolomics competency to enable, accelerate, and support drug development through biomarker discovery, understanding mechanism of action, patient stratification and more. Day has a strong track record in achieving significant improvements in key performance metrics associated with the different phases of clinical testing. He has experience with numerous testing method regulations and certifications. His role will focus on evolving Metabolon’s capability to leverage clinical metabolomics to drive precision medicine forward.
“Metabolomics represents the next level in understanding human health because metabolites go beyond ‘risk’ to illuminate the current health state of a biological system,” says Day. “I am motivated by the opportunity to support Metabolon in becoming a leading player in the precision healthcare space by driving improved decision-making and laboratory efficiencies for our clients as they develop new therapeutic options to advance patient care and outcomes.”
